LBRX

Conviction 57HealthcareScan · Thu, Jun 25, 2026

LBRX$30.96+1.57%

ResistanceSupportVol 14

Vol MA14 285.46K

Mar 26Apr 14May 1May 19Jun 8Jun 25

LB PHARMACEUTICALS INCBiotechnologywww.lbpharma.us ↗

Price30.96

Change+1.57%

Gap+2.82%

Rel volume0.91×

Avg volume255.21K

Avg $ vol7.49M

SMA 2028.90

SMA 5029.86

SMA 200—

Price vs 50+3.70%

Price vs 200—

MA stack—

50/200 cross—

Supertrenddown · 32.38

RSI (14)61

MACD hist0.30

MACD crossbull · 5d

Stoch %K / %D79 / 76

ADX (14)17

+DI / −DI20 / 12

RSI divergence—

MACD divergence—

ATR %+5.44%

ADR %5.76%

52w high32.88

52w low14.61

From 52w high-5.84%

Above 52w low+111.91%

New 52w highNo

SqueezeFired

Bollinger width15.12%

%B0.97

Donchian pos82.55%

Donchian high31.93

Donchian low26.37

AVWAP (52w high)29.79

vs AVWAP high+3.93%

AVWAP (52w low)23.33

vs AVWAP low+32.69%

OBV trendFlat

Chaikin MF (20)-0.20

Today vs 20d0.91×

Avg vol (14d)285.46K

Avg vol (20d)255.21K

Avg $ vol (20d)7.49M

Market cap887.83M

RS 3m (vs SPY)+18.17%

RS 6m (vs SPY)+36.92%

RS line new highNo

Trend template—

Technical rank85.1

1 week+3.03%

1 month+9.28%

3 months+27.88%

6 months+37.36%

1 year—

YTD+51.47%

P/E-35.22

P/B2.34

P/S—

P/FCF-25.18

EPS-3.13

Div yield—

ROE-6.66%

ROA-6.41%

Debt/Eq—

Current35.68

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth60.06%

Price target46.83

Target upside51.26%

Analyst ratingBuy

Institutional102.63%

Ent. value567.15M

Revenue—

Net income-19.05M

Gross profit—

Free cash flow-35.26M

IndustryBiotechnology

ExchangeNasdaq

Shares out28.68M

Employees27

ListedThu, Sep 11, 2025

Free float23.84M

Float %83.2%

Short interest4.02M

Days to cover21.8d

Short volume42.0%

Squeeze score60 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.67 vs −$0.75

Last surprise+10.7% beat

Setup gradeC

Conviction57 / 100

Pattern quality—

Tech rank85.1 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance33.45

Support26.44

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in LBRX

All disclosures →

No recent disclosed trades by Congress in LBRX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in LBRX · 7 buys

Insider	Side	Shares	Value	Traded	Filed
Garland J. Scott Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05
RUFFOLO ROBERT R Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05
Hemrajani Rekha Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05
Nussbaum Ran Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05
Kane William P Jr Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05
Lenz Robert A. Director · Stock Option (Right to Buy) · 2026-06-03	Grant	12.5K	$0	2026-06-03	2026-06-05
Luse Rebecca Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05

SEC filings

EDGAR filings in LBRX · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.